Unpleasant truth: the pandemic, record debt and our opportunity for sustainability
pharmaphorum
SEPTEMBER 8, 2020
Beyond significant cost savings, biosimilar uptake has been shown to simultaneously improve patient access, varying by country. A subsequent change in guidance moved this biologic to a first-line treatment, resulting in an increase in the number of patients who could receive this much-needed treatment by 104%.
98 
Let's personalize your content